Unexpected Discharge from an Implanted Automatic Defibrillator

The occurrence of inappropriate discharge from an implanted cardioverter-defibrillator is reported. The device was triggered by an episode of induced nonsustained ventricular tachycardia, and the shock was delivered 10 sec after spontaneous termination of the arrhythmia.
This observation demonstrates that unexpected discharges from an implanted cardiaverter/defibrillator can occur while the patient is asymptomatic. In order to avoid such an adverse effect, improvement of the detection system of the device is advisable.     

Peptide-urea interaction

The excess enthalpies of the ternary aqueous solutions containing urea and the glycyl-glycine, glycyl-L-alanine, L-alanyl-L-alanine and sarcosyl-sarcosine diketopiperazines respectively have been determined. A weak but favourable enthalpic contribution to the interaction between these solutes is found. The difference between “strong” and “weak” interactions in aqueous solutions of non-electrolytes is stressed and the role of water in the weak, non-specific interactions, is discussed. The consequence of the weakness of the urea-peptide interactions on the binding of urea to the proteins is also briefly discussed.     

Efficacy and Safety of Ventricular Rate Responsive Pacing in Children with Complete Atrioventricular Block

Single chamber rate responsive pacing offers many potential advantages over the more complex dual chamber atrial tracking pacing mode in children, and the preservation of atrioventricular synchrony could be unnecessary in selected groups of pediatric patients. Twenty-two pediatric patients (age range 9 months to 12 years; mean 6.5 years) had implantation of ventricular rate responsive (VVIR) pacemakers over a 2-year period. All patients had chronic third-degree atrioventricular block, and a normal ventricular function at rest. During the follow-up each patient underwent a 24-hour Holter monitoring, and ten performed a graded treadmill test in both ventricular fixed rate (VVI) and rate responsive (VVIR) pacing mode. Paced ventricular rates were found to be normal for age in all 22 patients; maximum rate did not reach the higher programmed rate during daily activities in any patient. Comparing the mean paced ventricular rate to the mean rates of blocked P waves, six patients showed a difference of more than 20 beats/min, which induced the pacemaker parameters to be reprogrammed. In all patients a significant correlation was found between variations of paced ventricular rate and variations of spontaneous blocked atrial rhythm (P < 0.05); this correlation persisted in the subsequent Holter controls in the ten patients with longer follow-up. Exercise tolerance resulted normal in the ten patients who performed a treadmill test either in VVIR or VVI mode, with increased maximal heart rates and maximal systolic blood pressure in VVIR mode (P < 0.0013). Rate responsive ventricular pacemakers seem to adequately respond to the physiological needs of daily life of this selected group of children requiring permanent pacing.     

The Automatic Implantable Cardioverter/Defibrillator; Transesophageal Atrial Pacing Discloses the Potential for Erroneous Discharges

We report the occurrence of erroneous discharge from an implanted automatic cardioverter/defibrillator during transesophageal atrial pacing. Transesophageal pacing was performed as part of a study protocol on the inducibility of ventricular tachycardia from the atrium in patients with ischemic heart disease. At an induced heart rate of 166 beats per minute (a value just above the cut-off rate of the device), the cardioverter/defibrillator was triggered. This observation suggests that transesophageal atrial pacing could be utilized to disclose the potential for spurious discharges in the event of fast atrial rhythms in patients with the automatic implantable cardioverter/defibrillator.     

COST-EFFECTIVE PHARMACOLOGICAL PREVENTION OF ACUTE CORONARY SYNDROMES

The growing size of trials on primary and secondary prevention of acute coronary syndromes characterised by very broad inclusion criteria may seem logical to `trialists', who reason that the broader the inclusion criteria, the easier it is to recruit large numbers of patients in a short period of time and the more widely applicable are the results of the study. However, large trials with very broad inclusion criteria raise two grounds for concern for physicians. The first is that the broader the inclusion criteria for enrolment in a trial in order to prove a statistically significant benefit, the greater the heterogeneity of the study population which is likely to include both susceptible and non-susceptible patients to the tested treatment. The second is that this method of assessment rapidly increases the number of treatments that produce a statistically-significant improvement in prognosis within the same broad group of patients. On the contrary, the identification of potential responders to a specific treatment can provide a personalised form of medical care suited to the needs of each individual patient with an optimal cost–benefit ratio. This approach, however, represents a major challenge as it can only be based on the identification of homogeneous subgroups of patients with common risk factors for the development of acute coronary syndromes or of their recurrence. This challenge can only be overcome by a strong commitment in funding studies on the multiple causes of acute coronary syndromes.